Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants

• Published in: Antiviral research Vol. 201; p. 105297
• Main Authors: Ueno, Mikako, Iwata-Yoshikawa, Naoko, Matsunaga, Akihiro, Okamura, Tadashi, Saito, Sho, Ashida, Shinobu, Yoshida, Isao, Nagashima, Mami, Asakura, Hiroyuki, Yaoita, Yuu, Suzuki, Jun, Sadamasu, Kenji, Yoshimura, Kazuhisa, Kutsuna, Satoshi, Shiwa-Sudo, Nozomi, Nagata, Noriyo, Suzuki, Tadaki, Suzuki, Akinori, Okamoto, Miwa, Kimura, Moto, Ohmagari, Norio, Miura, Ryu, Ishizaka, Yukihito
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2022; The Authors. Published by Elsevier B.V
• Subjects: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antineoplastic Agents, Immunological; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; COVID-19 Drug Treatment; Drug Combinations; Escape mutants; Humans; Leukocytes, Mononuclear; mAb; Neutralizing activity; Omicron variants; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Spike protein; SARS-CoV-2; Escape mutants; Spike protein; Neutralizing activity; Omicron variants; mAb

Monoclonal antibody therapy is a promising option for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a cocktail of antibodies (REGN-COV) has been administered to infected patients with a favorable outcome. However, it is necessary to continue generating novel sets of mon...